Evidence map›Paper›PMID 26542764›Full record

ArticleScientific reports2015

A high risk of osteosarcoma in individuals who are homozygous for the p.D104N in endostatin.

Wen-Zhi Bi, Dian-Wei Li, Song Luo, Zhi-Gang Song, Yun Wang, Hua Jin, Yan Wang, Qing Li, Meng-Xia Li, Dong Wang and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Wen-Zhi BiDepartments of Orthopaedics, The General Hospital of Chinese People's Liberation Army, Beijing 100853, China.
Dian-Wei LiDepartments of Orthopaedics, The General Hospital of Chinese People's Liberation Army, Beijing 100853, China.
Song LuoDepartments of Orthopaedics, The General Hospital of Chinese People's Liberation Army, Beijing 100853, China.
Zhi-Gang SongDepartment of Pathology, The General Hospital of Chinese People's Liberation Army, Beijing 100853, China.
Yun WangDepartment of Pathology, The General Hospital of Chinese People's Liberation Army, Beijing 100853, China.
Hua JinDepartment of Molecular Pharmacology and Physiology, University of South Florida Health Sciences Center, Tampa, FL 33647, USA.
Yan WangDepartments of Orthopaedics, The General Hospital of Chinese People's Liberation Army, Beijing 100853, China.
Qing LiCancer Center, Daping Hospital and Research Institute of Surgery, The Third Military Medical University, Chongqing 400042, China.
Meng-Xia LiCancer Center, Daping Hospital and Research Institute of Surgery, The Third Military Medical University, Chongqing 400042, China.
Dong WangCancer Center, Daping Hospital and Research Institute of Surgery, The Third Military Medical University, Chongqing 400042, China.
Bo SunState Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China.
Meng XuDepartments of Orthopaedics, The General Hospital of Chinese People's Liberation Army, Beijing 100853, China.
Cheng-Xiong XuCancer Center, Daping Hospital and Research Institute of Surgery, The Third Military Medical University, Chongqing 400042, China.
Chinese People's Liberation Army · CNArmy Medical University · CNDaping Hospital · CNPeople's Liberation Army No. 150 Hospital · CNSoutheast University · CNUniversity of South Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The D104N polymorphism (p.D104N) in endostatin has been previously identified in many types of cancer, and this polymorphism is believed to be a phenotypic modulator in some tumors. However, it is unknown whether endostatin p.D104N affects the risk and progression of osteosarcoma (OS). Here, we analyzed the p.D104N endostatin variant in 236 patients with OS and 418 healthy individuals. Similar frequencies of wild type and heterozygous p.104DN endostatin were observed in controls and OS patients. Interestingly, the frequency of the homozygous p.D104N (p.104NN) genotype was higher in OS patients group compared to control group, suggesting that individuals with p.104NN endostatin have a significantly increased risk for OS. In addition, OS patients with p.104NN endostatin had a shorter survival time and a higher rate of metastasis than OS patients with wild type endostatin. Animal experiments revealed that overexpression of p.104NN endostatin did not significantly inhibit OS lung metastasis. Interestingly, administration of endostatin dramatically inhibited OS lung metastasis in the p.104NN endostatin xenograft model. Together, these results suggest that p.104NN of endostatin is associated with the risk of OS and demonstrates predictive significance for clinical outcome in OS patients. In addition, endostatin therapy may be necessary for OS patients harboring p.104NN endostatin.

Indexed as

HomozygoteEndostatinsHumansOsteosarcomaPolymorphism, GeneticEndostatins

Identifiers

PMID26542764
PMCPMC4635404
OpenAlexW2410787363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.